source
- Novo Nordisk halts two cardiovascular trials of inflammation-targeting drug ziltivekimabNovo Nordisk announced it is halting the HERMES and ATHENA cardiovascular trials of its experimental drug ziltivekimab, which was intended to lower inflammation to improve heart health. A data mon…
- BrainChild Bio masterminds $116M series A for CAR-T's pivotal push in pediatric brain cancerA startup spawned from Seattle Children’s Hospital has raised a $116 million series A to advance cell therapies for devastating childhood brain tumors.